Thrasos Therapeutics, a Canada-based drug developer focused on acute kidney injuries, has raised $35m from a consortium led by drugs company GlaxoSmithKline’s (GSK) corporate venturing unit.

SR One’s commitment came from its GSK Canada Life Sciences Innovation Fund set up at the end of last year.

Jens Eckstein, president of SR One, said: “Thrasos’ lead therapeutic program for acute kidney injury [THR-184] has demostrated strong potential in preliminary studies.”

GSK was joined by investment group SW Company as a repeat…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?